RxDoctor Payments Data

Thomas Yuen, MD

Family Medicine · Chester, NYNPI 1992867055

Payments from drug & device makers

$5,076in general payments, 2019–2025

Across 268 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$939
  • AstraZeneca$816
  • Lilly USA, LLC$691
  • Novo Nordisk$619
  • Pfizer$525
  • Gilead$277
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$5,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,076 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$130,676
Medicare patients
258
Services billed
4,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$52,677
JardianceEmpagliflozin24$38,478
EliquisApixaban21$36,117
MounjaroTirzepatide20$27,916
FarxigaDapagliflozin Propanediol14$17,680
XareltoRivaroxaban12$16,226
Duloxetine Hcl50$2,498
Rosuvastatin Calcium124$1,887
Albuterol Sulfate HfaAlbuterol Sulfate55$1,855
Levothyroxine Sodium99$1,394
Lidocaine11$1,348
Ezetimibe16$1,003
Pantoprazole Sodium47$877
Atorvastatin Calcium83$790
Valsartan16$661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$619$52,67731 claims
Boehringer IngelheimJardiance$120$38,47824 claims
PfizerEliquis$525$36,11721 claims
Lilly USA, LLCMounjaro$691$27,91620 claims
AstraZenecaFarxiga$816$17,68014 claims
Johnson & JohnsonXarelto$15$16,22612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.

Other family medicine in Chester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →